ASX News
TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma multiforme
Telix Pharmaceuticals is pleased to release an update on the progress of its TLX101 product being developed for the treatment of glioblastoma multiforme (GBM, brain cancer). The IPAX-1 clinical trial, which is testing TLX101 combined with external beam radiation therapy in patients with recurrent GBM, is recruiting to plan. Early study outcomes appear encouraging.
To read the full media release please click here.
More Articles
ASX News
Activities Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th...
ASX News
Telix Pharmaceuticals Receives $11.4M R&D Tax Refund
Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to...
ASX News
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
ASX News
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...
Corporate Spotlight
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)
Corporate Spotlight
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
1st May 2020 - Corporate Spotlight | Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe...